Evidence map›Paper›PMID 21311504›Full record

Trial reportAmerican journal of hypertension2011

Vitamin D3 supplementation for 16 weeks improves flow-mediated dilation in overweight African-American adults.

Ryan A Harris, Jennifer Pedersen-White, De-Huang Guo, Inger S Stallmann-Jorgensen, Daniel Keeton, Ying Huang, Yashesh Shah, Haidong Zhu, Yanbin Dong

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of hypertension, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 6 pooled it
16.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 6 syntheses or guidelines pooled it, 157 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Raynaud's phenomenon and vitamin D.Rheumatology international · 2013
    Trial
  18. Trial
  19. Trial
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ryan A HarrisGeorgia Prevention Institute, Department of Pediatrics, Medical College of Georgia, Augusta, USA.
Jennifer Pedersen-White
De-Huang Guo
Inger S Stallmann-Jorgensen
Daniel Keeton
Ying Huang
Yashesh Shah
Haidong Zhu
Yanbin Dong
Augusta University · USPrevention Institute · US

Funding

Genetics of Stress Induced Hypertension in Black YouthR01HL077230 · NHLBI · AUGUSTA UNIVERSITY · PI DONG, YANBIN · 2006 to 2009
$1.4M
NHLBI NIH HHS HL077230NHLBI NIH HHS R01 HL077230
6 · The paper itself

Abstract

backgroundA growing body of evidence has linked vitamin D deficiency to increased risk of cardiovascular disease. Vitamin D deficiency is also more common in African Americans for whom an increased cardiovascular disease risk exists. This study sought to test the hypothesis that 16 weeks of 60,000 IU monthly supplementation of oral vitamin D(3) would improve flow-mediated dilation (FMD) in African Americans, whereas no change would be observed in the placebo group.

methodsA randomized, double-blind, placebo-controlled clinical trial was conducted. Fifty-seven African-American adults were randomly assigned to either the placebo group or vitamin D group.

resultsFollowing 16 weeks of placebo (n = 23; mean age 31 ± 2 years) or 60,000 IU monthly oral vitamin D(3) (n = 22; mean age 29 ± 2 years), serum concentrations of 25-hydroxyvitamin D (25(OH)D) increased from 38.2 ± 3.0 to 48.7 ± 3.2 nmol/l and 34.3 ± 2.2 to 100.9 ± 6.6 nmol/l, respectively. No changes in serum parathyroid hormone (PTH), serum calcium, or urine calcium/creatinine were observed following either treatment. Following 16 weeks of treatment, significant improvements in FMD were only observed in the vitamin D group (1.8 ± 1.3%), whereas the placebo group had no change (-1.3 ± 0.6%). Similarly, the vitamin D group exhibited an increase in absolute change in diameter (0.005 ± 0.004 cm) and FMD/shear (0.08 ± 0.04 %/s(-1), area under the curve (AUC) × 10(3)) following treatment, whereas no change (-0.005 ± 0.002 cm and -0.02 ± 0.02 %/s(-1), AUC, respectively) was observed following placebo.

conclusionSupplementation of 60,000 IU monthly oral vitamin D(3) (~2,000 IU/day) for 16 weeks is effective at improving vascular endothelial function in African-American adults.

Indexed as

Black or African AmericanVasodilationAdultCholecalciferolDietary SupplementsDouble-Blind MethodEndothelium, VascularFemaleHumansMaleOverweightVitamin DVitamin D Deficiency25-hydroxyvitamin DCholecalciferolVitamin D

Identifiers

PMID21311504
PMCPMC3812921
OpenAlexW2059078758

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.